PTC Therapeutics walked into fractious controversy when it bought the rights to a costly treatment for Duchenne muscular dystrophy. Now, with a pair of lawmakers pressuring the company to slash the drug’s price, the small biotech is politically penned in and running out of money.
The drug, Emflaza, carried an $89,000 annual list price when it won Food and Drug Administration approval in February, and PTC, which licensed it last week, has promised to bring that number down — but it’s yet to pick a price.
About the Author Reprints
